(Q40601552)

21 September 2017

title

Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases (English)

1 reference

21 September 2017

Gandhi SK

1

1 reference

21 September 2017

Arguelles L

series ordinal

2

1 reference

21 September 2017

Boyer JG

series ordinal

3

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

21 September 2017

1 reference

21 September 2017

volume

21

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

684-690

1 reference

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Management of fever in patients with cancer and treatment-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Economic study of neutropenia induced by myelotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

The costs of treating febrile neutropenia in six U.K. Hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

The distinction between cost and charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.7.684.34568

10.1592/PHCO.21.7.684.34568

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference